Onvansertib, in combination with the PI3Kα inhibitor alpelisib, has been shown to synergistically inhibit cell viability and suppress PI3K signaling in PIK3CA-mutant HR + breast cancer both in vitro and in vivo (Sreekumar et al., 2024). This evidence concerns the gene PIK3CA and breast carcinoma.